Celltrion To Invest $33.6bn As It Lays Out Long-Term Ambitions

May 20 2019

• By Jung Won Shin

Listen to this article

Celltrion unveils massive long-term investment plan to secure leadership in the global biopharma market, set up international sales distribution networks and support new bioventures and job creation, in the meantime contributing to Korea’s larger ambitions to develop as a worldwide drug industry hub.

Arrows — Celltrion Unveils Huge Investment Plan For Global Ambitions • Source: Shutterstock

Celltrion Inc., which has recently announced plans to establish its own global direct sales and distribution networks to seek further growth and improve margins, aims to invest a massive KRW40tn ($33.6bn) over the next 10 years in both biologics and chemical drugs, and in worldwide healthcare and U-healthcare (ubiquitous healthcare) platform businesses under a new long-term road map.

“Celltrion Group feels responsible as a leading South Korean biopharma firm and will focus on businesses that can beef up...

More from South Korea

Emerging Modalities Stand Out In Recovering Korean Deal Market
Aug 23 2024
• By Jung Won Shin
While Korean biopharma companies’ out-licensing deals have remained lackluster in the past couple of years, activity around emerging modalities, led by ADCs, have been increasing in line with global trends.
Korean Biopharma Financings Remain In Doldrums But Recovery In Sight?
Aug 13 2024
• By Jung Won Shin
As investor sentiment around Korean biopharma IPOs and financings remained tepid in the second quarter, companies turned to other ways of raising money, including rights offerings. But there are signs of recovery and upcoming catalysts, while on the M&A front Boryung divested a vaccine subsidiary to a private equity consortium.
Korea Q2 Roundup: Hanmi Dispute Simmers, Emerging Obesity Focus
Aug 09 2024
• By Jung Won Shin
As it reported mixed second-quarter earnings, South Korea's pharma industry is increasingly turning to obesity pipeline assets. Meanwhile, leadership disputes among family members within Hanmi are resurfacing.
S.Biomedics’ Parkinson's Cell Therapy Shows Early Clinical Promise
Jul 30 2024
• By Jung Won Shin
A novel stem cell therapy for Parkinson’s disease developed by a Korean firm has shown what Citeline analysts describe as "very promising" early clinical results at a low dose after one year.

More from Focus On Asia

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2
Oct 14 2025
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval
Mar 10 2025
• By Dexter Jie Yan
The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.
As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS
Mar 10 2025
• By Mandy Jackson
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.